Flu season starts, but demand for cough-cold meds remains weak

Impact in US among the worst in the past 10 years

Demand in India for cough and cold medicines remained weak even as the US witnessed one of the worst beginnings to the season the past decade.
 

Analysts at Nuvama Research said key findings show five times more illness versus the average of the last five years, eight times more hospital visits, and 3.5 times more deaths this season in the US.
 

Indian companies stand to gain as a result of a strong flu season as they enjoy a one-third share of the total prescription market in Oseltamivir (flu medicine) suspension market.
 

Oseltamivir is the first-line treatment for Influenza A and